Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:12:00.063Z.
Calculation as of: 2026-10-06T14:12:00.063Z.
Quote observation: 2026-10-06T14:10:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$137.57M
EV/EBIT Ratio
N/A
TTM Avg
734.52x
3Y Avg
360.78x
5Y Avg
245.93x
Market Cap
$139.95M
EV/EBIT Ratio
N/A
TTM Avg
60.31x
3Y Avg
490.71x
5Y Avg
419.04x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Freenome, Inc. (FRNM) | $138.47M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.57M | N/A | 734.52x | 360.78x | 245.93x |
| Alpha Cognition Inc (ACOG)vs › | $140.09M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $139.95M | N/A | 60.31x | 490.71x | 419.04x |
| LifeMD, Inc. (LFMD)vs › | $135.83M | N/A | 204.78x | 204.78x | 204.78x |
| Fortress Biotech, Inc. (FBIOP)vs › | $141.70M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $144.79M | N/A | N/A | N/A | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $131.16M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.71M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $148.07M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
